Estimation the Safety of Parenteral Resveratrol in Mice

Rehab AM. Jawad, H. Sahib
{"title":"Estimation the Safety of Parenteral Resveratrol in Mice","authors":"Rehab AM. Jawad, H. Sahib","doi":"10.31351/vol31iss1pp167-175","DOIUrl":null,"url":null,"abstract":"   Resveratrol is polyphenolic compound has many biochemical and biological effects on several organs. Therefore, resveratrol can be used to treat many diseases. The aim was to evaluate resveratrol safety when used in a parenteral single bolus dose. This study was conducted on 60 mice (30 males and 30 females). Each male and female mice divided into 6 groups (five mice per group). All mice groups given 1% DMSO and five different doses of resveratrol (5, 2.5, 1.25, 0.625, 0.312) gm/kg intraperitonially given to five groups respectively. The mice were continuously monitored during 14 days. The number of deaths, changes in general behavior, changes in physiological activity, and signs of toxicity were reported. On day 15 blood was collected using a jugular vein puncture to obtain blood samples for hematological and biochemical analysis. All mice were euthanized under anesthesia. The heart, lung, liver, kidney, and gonads were dissected and sent for histopathological study. The result showed that at dose 0.312gm/kg neither signs of toxicity nor death were detected. The LD50 dose was 1.18 g/kg for female and 1.07 g/kg for male mice. The body weight change, biochemical and hematological assay, revealed that at doses 1.25 g/kg,0.625,0.312 g/kg for both sexes no significant changes had reported in comparison with a control group (p?0.05). Histopathological examination revealed that at doses 1.25 g/kg for both sexes no significant tissue changes had reported in comparison with a control group (p?0.05). In conclusion resveratrol has dose-dependent toxicity when used intraperitoneally in Swiss Albino mice and the non-observed adverse effect level at dose 0.312 g/kg.","PeriodicalId":14509,"journal":{"name":"Iraqi Journal of Pharmaceutical Sciences ( P-ISSN: 1683 - 3597 , E-ISSN : 2521 - 3512)","volume":"1 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2022-06-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Iraqi Journal of Pharmaceutical Sciences ( P-ISSN: 1683 - 3597 , E-ISSN : 2521 - 3512)","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.31351/vol31iss1pp167-175","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 1

Abstract

   Resveratrol is polyphenolic compound has many biochemical and biological effects on several organs. Therefore, resveratrol can be used to treat many diseases. The aim was to evaluate resveratrol safety when used in a parenteral single bolus dose. This study was conducted on 60 mice (30 males and 30 females). Each male and female mice divided into 6 groups (five mice per group). All mice groups given 1% DMSO and five different doses of resveratrol (5, 2.5, 1.25, 0.625, 0.312) gm/kg intraperitonially given to five groups respectively. The mice were continuously monitored during 14 days. The number of deaths, changes in general behavior, changes in physiological activity, and signs of toxicity were reported. On day 15 blood was collected using a jugular vein puncture to obtain blood samples for hematological and biochemical analysis. All mice were euthanized under anesthesia. The heart, lung, liver, kidney, and gonads were dissected and sent for histopathological study. The result showed that at dose 0.312gm/kg neither signs of toxicity nor death were detected. The LD50 dose was 1.18 g/kg for female and 1.07 g/kg for male mice. The body weight change, biochemical and hematological assay, revealed that at doses 1.25 g/kg,0.625,0.312 g/kg for both sexes no significant changes had reported in comparison with a control group (p?0.05). Histopathological examination revealed that at doses 1.25 g/kg for both sexes no significant tissue changes had reported in comparison with a control group (p?0.05). In conclusion resveratrol has dose-dependent toxicity when used intraperitoneally in Swiss Albino mice and the non-observed adverse effect level at dose 0.312 g/kg.
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
小鼠静脉注射白藜芦醇的安全性评价
白藜芦醇是一种多酚类化合物,对多种器官具有多种生物化学作用。因此,白藜芦醇可用于治疗多种疾病。目的是评估白藜芦醇在单次静脉注射时的安全性。本研究在60只小鼠(30只雄性和30只雌性)上进行。每只雌雄小鼠分为6组(每组5只)。各组小鼠分别给予1% DMSO和5种不同剂量(5、2.5、1.25、0.625、0.312)gm/kg白藜芦醇灌胃。在14天内对小鼠进行连续监测。报告了死亡人数、一般行为变化、生理活动变化和中毒迹象。第15天采用颈静脉穿刺采血,采集血样进行血液学和生化分析。所有小鼠均在麻醉下安乐死。解剖心、肺、肝、肾、性腺,送组织病理检查。结果表明,在0.312gm/kg剂量下,未发现毒性和死亡迹象。雌性小鼠LD50为1.18 g/kg,雄性小鼠LD50为1.07 g/kg。体重变化,生化和血液学分析显示,在1.25 g/kg,0.625,0.312 g/kg剂量下,与对照组相比,两性均无显著变化(p?0.05)。组织病理学检查显示,在1.25 g/kg剂量下,与对照组相比,两性均未报告明显的组织变化(p?0.05)。结论白藜芦醇对瑞士白化病小鼠腹腔注射具有剂量依赖性毒性,剂量为0.312 g/kg时未观察到不良反应水平。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
Evaluation of Renoprotective Effect of Lipoic Acid and Bosentan Against Diclofenac-Induced Acute Renal Failure Assessment of Certain Hematological Indices and Interlukin-6 in Workers and Individuals Who Live Near to Crude Oil Wells in Middle Petroleum Subchronic effect of different doses ofDiclofenac Sodium on female reproductive system in rats. Evaluating the Benefits of Using Mobile Application (diarrhea management step by step) in the Management of Diarrhea by Community Pharmacists Study anti-inflammatory effect of Tamsulosin in rat by evaluation IL-4, IL-6 and TNF-α: airway model.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1